Literature DB >> 25108739

Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.

Mala Pande1, Melissa L Bondy, Kim-Anh Do, Aysegul A Sahin, Jun Ying, Gordon B Mills, Patricia A Thompson, Abenaa M Brewster.   

Abstract

Obesity-related hormones and cytokines alter PI3 K-AKT-mTOR pathway activation in breast tumors contributing to poorer disease-free survival (DFS) and decreased responsiveness to tamoxifen and trastuzumab. We hypothesized that single nucleotide polymorphisms (SNPs) in candidate genes in the PI3 K-AKT-mTOR signaling pathway may act as genetic modifiers of breast cancer DFS. We analyzed the association of 106 tagging SNPs in 13 genes (ADIPOQ, IGF1, INS, IRS1, LEP, LEPR, LEPROT, PIK3CA, PIK3R5, PTEN, TSC1, TSC2, and AKT1) in the P13K-AKT-mTOR pathway with DFS in a sample of 1,019 women with stage I-II breast cancer. SNPs significantly associated with DFS in any genetic model (additive, dominant, or recessive) after correcting for false discovery rate (FDR = 0.10) were included in Cox proportional hazards multivariable analyses. After adjusting for race/ethnicity, age at diagnosis, tumor stage, and treatment, rs1063539 in ADIPOQ, rs11585329 in LEPR, and rs2519757 in TSC1 were associated with improved DFS, and rs1520220 in IGF1 and rs2677760 in PIK3CA were associated with worse DFS. The associations were not significantly modified by the type of systemic treatment received or body mass index. The SNPs were not associated with tumor characteristics such as tumor size, lymph node status, nuclear grade, or hormone receptor status. In this study, germline SNPs in the PI3 K-AKT-mTOR pathway were associated with breast cancer DFS and may be potential prognostic markers. Future studies are needed to replicate our results and to evaluate the relationship between these polymorphisms and activation of the PI3 K-AKT-mTOR pathway in breast tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25108739      PMCID: PMC4174407          DOI: 10.1007/s10549-014-3081-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

1.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.

Authors:  Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson
Journal:  Am J Hum Genet       Date:  2003-12-15       Impact factor: 11.025

Review 2.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

3.  The International HapMap Project Web site.

Authors:  Gudmundur A Thorisson; Albert V Smith; Lalitha Krishnan; Lincoln D Stein
Journal:  Genome Res       Date:  2005-11       Impact factor: 9.043

Review 4.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

Review 5.  mTOR, translation initiation and cancer.

Authors:  Y Mamane; E Petroulakis; O LeBacquer; N Sonenberg
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

6.  AKT activation predicts outcome in breast cancer patients treated with tamoxifen.

Authors:  Tove Kirkegaard; Caroline J Witton; Liane M McGlynn; Sian M Tovey; Barbara Dunne; Alison Lyon; John M S Bartlett
Journal:  J Pathol       Date:  2005-10       Impact factor: 7.996

7.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

Review 8.  Mammalian target of rapamycin inhibition.

Authors:  Janice P Dutcher
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

9.  Relationship between epidemiologic risk factors and breast cancer recurrence.

Authors:  Abenaa M Brewster; Kim-Anh Do; Patricia A Thompson; Karin M Hahn; Aysegul A Sahin; Yumei Cao; Maureen M Stewart; James L Murray; Gabriel N Hortobagyi; Melissa L Bondy
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

10.  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.

Authors:  Elin Karlsson; Gizeh Pérez-Tenorio; Risul Amin; Josefine Bostner; Lambert Skoog; Tommy Fornander; Dennis C Sgroi; Bo Nordenskjöld; Anna-Lotta Hallbeck; Olle Stål
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

View more
  11 in total

1.  Transcriptomic analysis reveals the role of a peptide derived from CRYAB on the CoCl2-induced hypoxic HL-1 cardiomyocytes.

Authors:  Xiaoshan Hu; Heng Liu; Mengmeng Li; Jingai Zhu; Zhangbin Yu
Journal:  J Thromb Thrombolysis       Date:  2021-02       Impact factor: 2.300

2.  Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications.

Authors:  Valeria Simone; Morena D'Avenia; Antonella Argentiero; Claudia Felici; Francesca Maria Rizzo; Giovanni De Pergola; Franco Silvestris
Journal:  Oncologist       Date:  2016-02-10

Review 3.  Molecular Biology in the Breast Clinics-Current status and future perspectives.

Authors:  Vani Parmar; Nita S Nair; Purvi Thakkar; Garvit Chitkara
Journal:  Indian J Surg Oncol       Date:  2019-08-10

Review 4.  Current advances in biomarkers for targeted therapy in triple-negative breast cancer.

Authors:  Brett Fleisher; Charlotte Clarke; Sihem Ait-Oudhia
Journal:  Breast Cancer (Dove Med Press)       Date:  2016-10-06

5.  Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer.

Authors:  Xueying Lu; Yanhong Li; Xiaobo Li; Haji Akber Aisa
Journal:  Oncol Lett       Date:  2017-06-14       Impact factor: 2.967

6.  The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway.

Authors:  Yazhuo Liu; Ruoyu Wang; Lichuan Zhang; Jianhua Li; Keli Lou; Bingyin Shi
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

Review 7.  Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects.

Authors:  Simona Granata; Alessandra Dalla Gassa; Amedeo Carraro; Matteo Brunelli; Giovanni Stallone; Antonio Lupo; Gianluigi Zaza
Journal:  Int J Mol Sci       Date:  2016-05-14       Impact factor: 5.923

8.  High DEPTOR expression correlates with poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Nan-Bo Liu; Jun-Hua Zhang; Yu-Fan Liu; Jun Li; Zhen-Zhong Zhang; Ji-Wei Li; Wen-Yue Liu; Chen Huang; Tao Shen; Cheng-Wei Gu; Dong-Yun Gao; Xia Wu; Xu Wu
Journal:  Onco Targets Ther       Date:  2015-11-19       Impact factor: 4.147

9.  Akt1 genetic variants confer increased susceptibility to thyroid cancer.

Authors:  Thomas Crezee; Mirela Petrulea; Doina Piciu; Martin Jaeger; Jan W A Smit; Theo S Plantinga; Carmen E Georgescu; Romana Netea-Maier
Journal:  Endocr Connect       Date:  2020-11       Impact factor: 3.335

10.  Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.

Authors:  Francesca Morgese; Davide Soldato; Silvia Pagliaretta; Riccardo Giampieri; Donatella Brancorsini; Mariangela Torniai; Silvia Rinaldi; Agnese Savini; Azzurra Onofri; Marina Scarpelli; Rossana Berardi
Journal:  Oncotarget       Date:  2017-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.